Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
For federal employees looking to maximize V savings….. after the BS I went through with BCBS I switched to Aetna. The copay for Vascepa on Aetna is $20.00 for a 90 day supply and with the savings card the total cost is zero. Next open enrollment you should check Aetna.
Thanks Captain I will post it this evening and mention the generic form of IPE is not approved for CVD risk reduction nor are they tested for oxidation.
Or should I say something else…. They seemed to be pushing the generic.
Captain, let me know if you can access this article from consumer labs on fish oil supplements. Only someone with your deep knowledge can set them straight. I saw a few recommendations made by them to be genuinely inadequate on this subject.
https://www.consumerlab.com/reviews/fish-oil-supplements-review/omega3/
Maybe this will help Amarin chip away at all those wasted lovazza prescriptions.
Did you file a complaint with OPM? If they get enough complaints they might actually do something.
LB, I switched to Aetna and my co pay for 90 days through Blink RX is zero. So glad I switched after fighting with them for a year.
We might need a letter writing campaign to Congress requesting safety tests and they can charge the generic companies for the tests.
I agree and was thinking the same thing and if I recall correctly, as a board we were looking into funding some lab tests. I think we concluded Amarin probably did this already and found nothing. Then again I/we could be wrong and I doubt anyone in the company will tell us.
I was hoping we could somehow get a class action suit for fraud if their formulation was found to be inferior. The only way to make them go away is to have them suffer a court loss or a big regulatory blow up….. a recall for product quality or someone actually tests their IPE and finds issues.
Thank you for posting those comments. I suspect the area of risk right now and the reason why pharma is staying away from Amarin is the anti trust suit. A crazy decision and the buyer can lose the entire value of the company. I think once that is done, and assuming it is positive to neutral to Amarin things will heat up. I just wish we had something to screw DRL and Hikma. I still think one might have a consumer fraud suit if their drug has any oxidation.
We are less than 2 months away from knowing whether they will be able to grow the US market with the current product. Win the appeal and it’s game on, get some enforceable boundaries and they will increase sales. I still want to hear if they have plans for the once a day version or combo pill. Those restore the CVD indication from generics.
Congratulations, I have the same thing that is monitored ever 2 years and 10 years running, no progression of plaque.
I switched from those MFers at BCBS to Fed Aetna and now pay nothing through for a 30 day supply through Blink.
You need a script and not sure why a doctor would say no if you are taking OTC. Better off taking V and reducing the pills you take to match the OTC dose.
You still need a prescription for V but blink does not carry generic V.
Some of you who are posting about the OTC EPA you are buying might consider using BlinkRX. A 30 day supply of Vascepa without insurance is only $99.00 with free shipping.
Hi Captain, you will definitely be better than me to respond to the author of this review. If you can’t reply to it send it to me and I will post it. I subscribe to this publication.
https://www.consumerlab.com/reviews/fish-oil-supplements-review/omega3/
One thing they have wrong is comparing the price of V to generic. Last I checked V is cheaper and those without insurance can get a 30 day supply for $99 at BlinkRx.
Unbelievable, for some that may remember Fep BCBS refused to cover V so I switched to Aetna Feds where V is preferred brand and covered. Just called blink to reorder and my co pay is only $10 and with the savings card I pay zero. Every Fed employee taking V should switch to Aetna next year.
No, the FEP portion of Blue will not cover V, only generic. Aetna Feds has V as the preferred brand so I switched.
Good news for you and it looks like coverage is expanding.
What plan are you on? I switched from Fed BCBS to Aetna to get V coverage. I was paying $99 per month to Blink.
You might be able to get the $99 per month from Blink which is what they charge me with no coverage.
Have you tried Blink RX, they charge me $99 for 30 days. Since I switched to Aetna in January I will be back to $9 for 90.
Sorry, the full name of the plan is Aetna open access basic….. no deductible.
Federal employees who lost Vascepa coverage under BCBS can switch now to Aetna basic and get Vascepa as the preferred brand. I am saying goodbye to BCBS but will file my complaints with OPM and the Maryland AG for forcing patients to take a drug that is not approved for Cardiovascular risk reduction.
Capt, do you happen to have handy the links to the Vascepa and generic labels? If not no worries I will look for them. I only have the V hard copy.
Rosemount, a suggestion if they try to swap your script and it’s a tactic I plan to use. I have one more appeal at BCBS and if they say no to V but yes to the generic then I plan to file an AG complaint. The issue I believe the state AG can address is the one of fraud. A pharmacy or insurance company cannot tell you they will only cover or fill the drug that is not FDA approved for your condition. Only your doctor can prescribe off label and if your doctor writes v then someone is committing fraud. In addition, if you call the pharmacy and find V is cheaper it furthers the fraud argument.
I suggest everyone do this and it only takes on state AG to take up the issue to cause all insurance companies to pause this practice.
Can’t we just sue on the basis of the label? If it’s not approved for the condition the generic should not be authorized? Moreover, the brand in two places I checked is cheaper leading me to believe there is some sort of discounting back to the insurance company. I wonder if there is a racketeering angle.
Sign me up for the class action…. I am impacted as well.
I think consumers need to punch these companies in the mouth. I can certainly understand covering generics when the labels are equal. But when the generic is not approved for the condition it’s fraud in my opinion. Insurance companies are committing consumer fraud and the AG incentive is nice big fines.
I will and really hope they approve it because it’s such a chore filing these things.
Capt, I am going through my last appeal with FEP BC/BS and taking the stance that the generic is not approved for my condition. What took so long is waiting for my Doctor to say to them V is for CVD risk reduction. I had a tough time convincing him the labels are different and the issue of possible oxidation with the generic. If they deny my appeal I told BCBS and my doctor I will file a state AG complaint of fraud on the basis the insurance is or practicing medicine through drug coverage. They can’t tell me they will only cover the drug not approved for my condition. I swear I believe we have a class action case.
If you scroll to the next drug Keytruda got the same treatment. Looks like all the EU players are looking to save some short term money and pay down the road for the MI or stroke. Inflation from the Ukraine war and our lack of oil output to meet demand is driving global inflation. Everyone is cutting back.
Did they ever provide an update on the once a day formula as a way to recapture the US? I would like to take a few less pills a day.
Can’t understand why it takes so long to deal with these cases. Just a big waste of taxpayer money.
Whatever happened to the infringement appeal against Hikma?
I am having the same fight and you need to have your doctor state your script is for cardiovascular risk reduction, reduce it indication. The generic is not approved. I have already told Fep BCBS I am filing a fraud complaint with my state AG. I just need to make sure my doctor sends them a clear message it’s for reduce it indication. We need to start filling fraud complaints on the insurance companies. They can’t tell you to take a drug that is not approved for your condition. I think these companies are getting rebates from these pharmacy management companies.
And hopefully an uptrend in sales and earnings.
This is usually a volatile period for the market and thanks to Bidenomics everything gets crushed.
In my opinion, this is nothing more than penny shorts trying to make a fast buck on fund quarter/ year end close. They are hedging we will see funds unload shares next week and they can continue real quick. The down volume has been low the whole past few weeks. I am mad at myself for buying a little more at $1.05 and will look to by more on 27 th. In my opinion, they will try to drop it as low as possible on that day and then cover. If funds don’t unload the shorts are screwed.
I don’t expect any positive news from Amarin until the start of October. Denner knows quarter- year -end close is a waste of good press.
Another MO conspiracy moron who distorts the reduce it results and then tries to compare it to results from DHA/EPA mix. I think he needs a lesson from the captain.
It’s possible it’s a timed hit piece for the Penny playing shorts or someone trying to accumulate. Funny how we are down hard and close a penny down from the prior day.
With almost a dollar a share in cash, no debt and revenues about to rise the current price is absurd and only reflects the uncertainty of the current management strategy.
FWIW, we should have known Italy would pass at this time. They are almost as broke as Greece, hit hardest by COVID and dealing with an immigration crisis.